Type 1 and type 2 diabetes, insulin resistance, glucose metabolism, and metabolic health
263 articles
A Japanese family case reveals how inherited HNF1A and ABCC8 mutations act additively to accelerate early-onset diabetes beyond either variant alone.
A newly identified mitochondrial NAD transporter in fat cells controls whether you develop obesity and insulin resistance as you age.
A newly discovered amygdala–liver neural circuit drives stress hyperglycemia independently of cortisol or adrenaline — and chronic stress breaks it.
Longevity experts endorse short CGM trials for non-diabetics, but RCT evidence remains thin. Here's what the data actually shows.
The FDA reportedly approved Eli Lilly's orforglipron, a daily oral GLP-1 receptor agonist for obesity, marking a potential shift from injectable weight-loss drugs.
A large Japanese cohort study shows polygenic risk scores predict T2D onset, yet exercise and metabolic health blunt even high genetic risk.
Longevity experts endorse CGMs for metabolic optimization, but RCT evidence in non-diabetics is still thin.
New research argues shared household metabolic factors — not just intrauterine exposure — drive MASLD risk in offspring.
Top longevity doctors endorse CGMs for healthy adults, but evidence is mixed. Here's what the 2026 device reviews reveal.
New composite biomarker combining inflammation, nutrition, and immunity markers shows promise for cardiovascular risk assessment.
Largest European study reveals widespread undiagnosed liver fibrosis, primarily linked to metabolic factors and alcohol use.
Orforglipron approved 294 days ahead of schedule for obesity treatment, marking first drug under new priority voucher system.
